Professor Wolf’s research focuses on defining the pathways that determine individual sensitivity to drugs and environmental chemicals. These pathways play a key role in disease susceptibility and in the outcome of drug therapy. Research in this area has provided one of the fundamental cornerstones in the development of the concept of stratified/personalised treatment of diseases such as cancer. After working in West Germany, USA and England, Professor Wolf headed the research labs in the Imperial Cancer Research Fund’s Medical Oncology Unit at the Western General Hospital in Edinburgh and subsequently led the ICRF Molecular Pharmacology group in the Biochemistry Department there. In 1992 Professor Wolf relocated to Dundee to establish the Biomedical Research Centre, subsequently the Biomedical Research Institute. Following a period as Director of the Medical Research Institute he is currently the Director of Strategic Development. Professor Wolf’s research has involved numerous academic collaborations as well as close collaborations with a wide range of pharmaceutical companies. In 2001 he founded the biotechnology company, CXR Biosciences, which provides pre-clinical drug development and chemical safety services to third parties, as well as having its own in-house drug discovery and development programme. He left CXR in 2012. Professor Roland Wolf was rewarded for his services to science with an OBE in the New Year’s Honours list in 2010.

Henderson, C.J , Cameron, A.R.,., Chatham, L., Stanley, L.A and Wolf, C.R. Evidence that the capacity of non-genotoxic carcinogens to induce oxidative stress is subject to marked variability. Tox. Sci. (2015 in Press) Henderson, C.J., McLaughlin, Scheer, N., Stanley, L.A., Wolf, C.R. Cytochrome b5 is a major detrerminant of human cytochrome P450 CYP3A4 and CYP2D6 activity in vivo. Molecular Pharmacology 87 733-9 (2015). Henderson, C.J., McLaughlin, L.A., McLaren, A.W., Wolf, C.R. A novel aryl receptor-Cre recombinase system applied to the conditional deletion of cytrochrome P450 oxidoreductase in mouse tissues. Biochem J. 465, 479-88 (2015). Henderson, C., McLaren, A., Wolf, C.R. In vivo regulation of human glutathione transferase GSTP by chemopeventitive agents. Cancer Research 74, 4378-4387(2014). Henderson, C.J., McLaughlin, L.A., and Wolf, C.R. Evidence that cytochrome b5 and cytochrome b5 reductase can act as sole electron donors to the hepatic cytochrome P450 system. Mol. Pharmacol. 83, 1209-1217 (2013). Scheer, N. and Wolf, C.R. Genetically humanized mouse models of drug metabolizing enzymes and transporters and their applications. Xenobiotica 2, 96-108 (2013). Scheer, N., Kapelyukh, Y., Chatham, L., Rode, A., Buechel, S. and Wolf, C.R. Generation and characterization of novel cytochrome P450 Cyp2c gene cluster knockout and CYP2C9 humanized mouse lines. Mol. Pharmacol. doi: 10.1124/mol.112.080036 (2012). Smith, G., Ng, M.T.H., Shepherd, L., Herrington, C.S., Gourley, C., Ferguson, M.J. and Wolf, C.R. Individuality in FGF1 expression significantly influences platinum resistance and progression free survival in ovarian cancer. Br. J. Cancer doi: 10.1038/bjc.2012.410 (2012). Scheer, N., Kapelyukh, Y., McEwan, J., Beuger, V., Stanley, L.A., Rode, A. and Wolf, C.R. Modelling human cytochrome P450 2D6 metabolism and drug-drug interaction by a novel panel of knockout and humanized mouse lines. Mol. Pharmacol. 81, 63-72 (2011). Henderson, C.J., Ritchie, K.J. (joint 1st authors), McLaren, A., Chakravarty, P. and Wolf, C.R. Increased skin papilloma formation in mice lacking glutathione S-transferase GSTP. Cancer Res. 71,7048-7060 (2011). Henderson, C.J. and Wolf, C.R. Knockout and transgenic mice in glutathione transferase research. Drug Metab. Rev. 43, 152-164 (2011). Hasegawa, M., Kapelyukh, Y., Tahara, H., Seibler, J., Rode, A., Krueger, S., Lee, D.N, Wolf, C.R. and Scheer, N.1 (1joint senior authors.) Quantitative prediction of human pregnane X receptor and cytochrome P450 3A4 mediated drug-drug interaction in a novel multiple humanized mouse line. Mol. Pharmacol. 80, 518-528 (2011). McLaughlin, L.A., Ronseaux, S., Finn, R.D., Henderson, C.J. and Wolf, C.R. Deletion of microsomal cytochrome b5 profoundly affects hepatic and extra-hepatic drug metabolism. Mol. Pharmacol. 78, 269-278 (2010). Ritchie, K.J., Walsh, S., Sansom, O.J., Henderson, C.J. and Wolf, C.R. Markedly enhanced colon tumorigenesis in Apc min mice lacking glutathione S-transferase Pi. Proc. Natl. Acad. Sci USA 106, 20859-64 (2009). Henderson, C.J., Scheer, N. and Wolf, C.R. Advances in the generation of mouse models to elucidate the pathways of drug metabolism in rodents and man. Expert Rev. Clin. Pharmacol. 2,105-109 (2009). Finn, R.D., Henderson, C.J., Scott, C.L. and Wolf, C.R. Unsaturated fatty acid regulation of cytochrome P450 expression via a CAR-dependent pathway. Biochem J., 417, 43-54 (2008). Finn, R.D., McLaughlin, L.A., Ronseaux, S., Rosewell, I., Houston, J.B., Henderson, C.J. and Wolf, C.R. Defining the in vivo role for cytochrome b5 in cytochrome P450 function through the conditional hepatic deletion of microsomal cytochrome b5. J. Biol. Chem. 283, 31385-31393 (2008). Wang, X. J., Hayes, J.D., Henderson, C.J. and Wolf, C.R. Identification of retinoic acid as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha. Proc. Natl. Acad. Sci. USA 104, 19589-19594 (2007). Ritchie, K.J., Henderson, C.J., Wang, X. J., Vassieva, O., Carrie, D., Farmer, P.B., Gaskell, M., Park, K. and Wolf, C.R. Glutathione transferase Pi plays a critical role in the development of lung carcinogenesis following exposure to tobacco-related carcinogens and urethane. Cancer Res. 67,9248-9257 (2007). Finn, R.D., McLaren, A.W., Carrie, D., Henderson, C.J. and Wolf, C.R. Conditional deletion of cytochrome P450 oxidoreductase in the liver and gastrointestinal tract: a new model for studying the functions of the P450 system. J. Pharmacol. Exp. Ther. 322, 40-47 (2007). Wang, X.J., Hayes, J.D. and Wolf, C.R. Generation of a stable antioxidant response element-driven reporter gene cell line and its use to demonstrate redox-dependent activation of Nrf2 (NF-E2 p45-related factor 2) by cancer chemotherapeutic agents. Cancer Res. 22, 10983-10994 (2006).